BR112017002221A2 - 2-(morfolin-4-il)-1,7-naftiridinas - Google Patents
2-(morfolin-4-il)-1,7-naftiridinasInfo
- Publication number
- BR112017002221A2 BR112017002221A2 BR112017002221-4A BR112017002221A BR112017002221A2 BR 112017002221 A2 BR112017002221 A2 BR 112017002221A2 BR 112017002221 A BR112017002221 A BR 112017002221A BR 112017002221 A2 BR112017002221 A2 BR 112017002221A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- morpholin
- naphthyridines
- preparation
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
2-(morfolin-4-il)-1,7-naftiridinas. a presente invenção está relacionada a compostos de 2-(morfolin-4-il)-1,7-naftiridina substituído da fórmula geral (i) ou (ib), nnr2nr1or4r3(i) nnr2nr1or4(ib) aos métodos de preparação dos compostos citados, aos compostos intermediários aplicáveis para a preparação dos compostos citados, às composições farmacêuticas e às combinações que consistem nos compostos citados para a fabricação de uma composição farmacêutica para tratamento ou profilaxia de uma doença, em particular de uma de uma doença hiperproliferativa como um agente isolado ou em combinação com outros ingredientes ativos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179692 | 2014-08-04 | ||
| EP14179692.0 | 2014-08-04 | ||
| EP15159342.3 | 2015-03-17 | ||
| EP15159342 | 2015-03-17 | ||
| PCT/EP2015/067804 WO2016020320A1 (en) | 2014-08-04 | 2015-08-03 | 2-(morpholin-4-yl)-l,7-naphthyridines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017002221A2 true BR112017002221A2 (pt) | 2018-05-22 |
| BR112017002221B1 BR112017002221B1 (pt) | 2023-02-28 |
Family
ID=53762196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017002221-4A BR112017002221B1 (pt) | 2014-08-04 | 2015-08-03 | 2- (morfolin-4-il)-1,7-naftiridinas, seus intermediários, combinação e composição farmacêuticas, combinação farmacêutica, e seus usos |
Country Status (42)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3177612T3 (da) | 2014-08-04 | 2022-05-16 | Nuevolution As | Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| EP3402795B1 (en) * | 2016-01-14 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JOP20190197A1 (ar) * | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
| CA3054248A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| CA3054247A1 (en) | 2017-02-24 | 2018-08-30 | Antje Margret Wengner | Combination of atr kinase inhibitors with parp inhibitors |
| WO2018153971A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors |
| WO2018153970A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| UY37616A (es) | 2017-02-24 | 2018-09-28 | Bayer Ag | Combinación de inhibidores de quinasa atr con sal de radio-223 |
| WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| US10377591B2 (en) | 2017-07-07 | 2019-08-13 | Zebra Technologies Corporation | Input handling for media processing devices |
| ES2974334T3 (es) | 2017-07-13 | 2024-06-26 | Univ Texas | Inhibidores heterocíclicos de ATR cinasa |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| EP3661560B1 (en) | 2017-08-04 | 2025-02-26 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
| US11897867B2 (en) | 2017-08-04 | 2024-02-13 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer |
| CN111886224B (zh) | 2017-08-17 | 2024-07-23 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
| WO2019057852A1 (en) | 2017-09-22 | 2019-03-28 | Bayer Aktiengesellschaft | USE OF KAP1 AS A BIOMARKER FOR DETECTION OR MONITORING ATR INHIBITION IN A SUBJECT |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| US11712440B2 (en) * | 2017-12-08 | 2023-08-01 | Bayer Aktiengesellschaft | Predictive markers for ATR kinase inhibitors |
| CA3090330A1 (en) * | 2018-02-07 | 2019-08-15 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | Atr inhibitor and application thereof |
| CN112218631B (zh) * | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
| SI3841101T1 (sl) | 2018-08-24 | 2023-07-31 | Bayer Aktiengesellschaft | Postopek priprave 2-((3R)-3- metilmorfolin-4-il)-4-(1-metil-1H-pirazol-5-il)-8-(1H-pirazol-5-il)-1,7 -naftiridina |
| WO2020078788A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| MA54091A (fr) * | 2018-10-30 | 2021-09-15 | Repare Therapeutics Inc | Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr |
| MA54928A (fr) | 2019-02-11 | 2021-12-22 | Bayer Ag | Inhibiteur de kinase atr bay1895344 destiné à être utilisé dans le traitement d'une maladie hyper-proliférative |
| CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
| JP2023502458A (ja) * | 2019-11-21 | 2023-01-24 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 |
| BR112022011426A2 (pt) * | 2019-12-11 | 2022-08-30 | Repare Therapeutics Inc | Uso de inibidores de atr em combinação com inibidores de parp |
| JP2021098692A (ja) | 2019-12-20 | 2021-07-01 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | 核内受容体に対して活性の化合物 |
| JP2023519603A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| WO2021198956A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| IL299510A (en) * | 2020-07-03 | 2023-02-01 | Antengene Discovery Ltd | Atr inhibitors and uses thereof |
| CN115943145A (zh) * | 2020-07-13 | 2023-04-07 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的吡唑并嘧啶化合物 |
| CN112110934B (zh) * | 2020-09-23 | 2021-12-07 | 上海应用技术大学 | 一种基于azd9291的生物标记物及其制备方法与应用 |
| US20240043419A1 (en) * | 2020-09-27 | 2024-02-08 | Medshine Discovery Inc. | Class of 1,7-naphthyridine compounds and application thereof |
| EP4267581A4 (en) * | 2020-12-25 | 2025-01-01 | Impact Therapeutics (Shanghai), Inc | SUBSTITUTED IMIDAZO[1,5-B PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND THEIR USE |
| BR112023024037A2 (pt) * | 2021-05-21 | 2024-02-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Sal farmaceuticamente aceitável de derivado de pirazoloheteroarila, formas cristalinas, composição farmacêutica, usos dos mesmos e métodos para preparar as referidas formas cristalinas e composição farmacêutica |
| KR20240041354A (ko) | 2021-07-27 | 2024-03-29 | 릿츠뜨 메디시네스 엘티디 | 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 |
| TWI831325B (zh) * | 2021-08-11 | 2024-02-01 | 大陸商微境生物醫藥科技(上海)有限公司 | 作為atr抑制劑的萘啶衍生物及其製備方法 |
| CN116283960A (zh) | 2021-12-21 | 2023-06-23 | 上海安诺达生物科技有限公司 | 取代的稠杂环化合物及其制备方法与应用 |
| CN116731011A (zh) * | 2022-03-01 | 2023-09-12 | 武汉众诚康健生物医药科技有限公司 | 一种萘啶衍生物及其应用 |
| CN116925070A (zh) * | 2022-04-24 | 2023-10-24 | 扬子江药业集团有限公司 | 取代的氮杂稠环化合物及其医药用途 |
| EP4539847A1 (en) | 2022-06-15 | 2025-04-23 | Astrazeneca AB | Combination therapy for treating cancer |
| WO2024188937A1 (en) | 2023-03-13 | 2024-09-19 | Bayer Aktiengesellschaft | Combinations of atr kinase inhibitors and parp inhibitors to treat hyper-proliferative conditions e.g. cancer |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
| US4008068A (en) * | 1976-03-08 | 1977-02-15 | Velsicol Chemical Corporation | 1-Thiadiazolyl-5-morpholinoimidazolidinones |
| WO2000058307A2 (en) | 1999-03-11 | 2000-10-05 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| JP5161102B2 (ja) * | 2005-11-22 | 2013-03-13 | クドス ファーマシューティカルズ リミテッド | ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体 |
| DE102005062742A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| ES2301380B1 (es) * | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
| WO2008023161A1 (en) * | 2006-08-23 | 2008-02-28 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| JP5564045B2 (ja) * | 2008-09-02 | 2014-07-30 | ノバルティス アーゲー | 二環式キナーゼ阻害剤 |
| EP2344490A2 (en) * | 2008-10-03 | 2011-07-20 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k |
| RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
| US20100144345A1 (en) | 2008-12-09 | 2010-06-10 | Microsoft Corporation | Using called party mobile presence and movement in communication application |
| WO2010071837A1 (en) | 2008-12-19 | 2010-06-24 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| US20110053923A1 (en) * | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2011143422A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| CA2803802A1 (en) * | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| MX2012015147A (es) * | 2010-06-30 | 2013-05-01 | Amgen Inc | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. |
| CN103562204A (zh) | 2011-04-05 | 2014-02-05 | 沃泰克斯药物股份有限公司 | 可用作tra激酶的抑制剂的氨基吡嗪化合物 |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US9096602B2 (en) | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
| US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN103957917A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| CN103958507A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物 |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| MX358818B (es) | 2012-04-05 | 2018-09-05 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa ataxia telangiectasia mutada y rad3 relacionados (atr) y terapias de combinacion de estos. |
| EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| ES2946360T3 (es) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
| JP6114313B2 (ja) | 2013-01-11 | 2017-05-24 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
| US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| EP3402795B1 (en) * | 2016-01-14 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| UY37616A (es) | 2017-02-24 | 2018-09-28 | Bayer Ag | Combinación de inhibidores de quinasa atr con sal de radio-223 |
| WO2018153971A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors |
| CA3054248A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| WO2018153970A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
| JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
| CA3054247A1 (en) | 2017-02-24 | 2018-08-30 | Antje Margret Wengner | Combination of atr kinase inhibitors with parp inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| AU2017421287A1 (en) | 2017-06-28 | 2020-01-23 | Corning Research & Development Corporation | Compact fiber optic connectors having multiple connector footprints, along with cable assemblies and methods of making the same |
| EP3661560B1 (en) | 2017-08-04 | 2025-02-26 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
| US11712440B2 (en) | 2017-12-08 | 2023-08-01 | Bayer Aktiengesellschaft | Predictive markers for ATR kinase inhibitors |
| SI3841101T1 (sl) | 2018-08-24 | 2023-07-31 | Bayer Aktiengesellschaft | Postopek priprave 2-((3R)-3- metilmorfolin-4-il)-4-(1-metil-1H-pirazol-5-il)-8-(1H-pirazol-5-il)-1,7 -naftiridina |
| MX2021003944A (es) | 2018-10-05 | 2021-07-16 | Isp Investments Llc | Composicion del recubrimiento de pelicula liso alto en solidos que comprende eter de celulosa soluble en agua, proceso para la preparacion de este y metodo de uso del mismo. |
| WO2020078788A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| MA54928A (fr) | 2019-02-11 | 2021-12-22 | Bayer Ag | Inhibiteur de kinase atr bay1895344 destiné à être utilisé dans le traitement d'une maladie hyper-proliférative |
-
2015
- 2015-07-30 TW TW104124794A patent/TWI656121B/zh active
- 2015-07-30 TW TW108109148A patent/TWI700283B/zh not_active IP Right Cessation
- 2015-08-02 JO JOP/2015/0186A patent/JO3447B1/ar active
- 2015-08-03 CA CA2956992A patent/CA2956992A1/en active Pending
- 2015-08-03 EA EA201891861A patent/EA035039B1/ru not_active IP Right Cessation
- 2015-08-03 SI SI201530327T patent/SI3177619T1/en unknown
- 2015-08-03 HR HRP20211770TT patent/HRP20211770T1/hr unknown
- 2015-08-03 HU HUE18167649A patent/HUE056676T2/hu unknown
- 2015-08-03 SG SG11201700750UA patent/SG11201700750UA/en unknown
- 2015-08-03 BR BR112017002221-4A patent/BR112017002221B1/pt active IP Right Grant
- 2015-08-03 CR CR20170034A patent/CR20170034A/es unknown
- 2015-08-03 DK DK18167649.5T patent/DK3395818T3/da active
- 2015-08-03 WO PCT/EP2015/067804 patent/WO2016020320A1/en not_active Application Discontinuation
- 2015-08-03 CU CU2017000009A patent/CU24419B1/es unknown
- 2015-08-03 HU HUE15744596A patent/HUE038533T2/hu unknown
- 2015-08-03 PL PL18167649T patent/PL3395818T3/pl unknown
- 2015-08-03 ES ES18167649T patent/ES2900599T3/es active Active
- 2015-08-03 EA EA201790306A patent/EA031678B1/ru not_active IP Right Cessation
- 2015-08-03 EP EP15744596.6A patent/EP3177619B1/en active Active
- 2015-08-03 AP AP2017009702A patent/AP2017009702A0/en unknown
- 2015-08-03 PH PH1/2017/500204A patent/PH12017500204B1/en unknown
- 2015-08-03 MX MX2020010333A patent/MX394442B/es unknown
- 2015-08-03 LT LTEP15744596.6T patent/LT3177619T/lt unknown
- 2015-08-03 CN CN201580053572.9A patent/CN106795156B/zh active Active
- 2015-08-03 PL PL15744596T patent/PL3177619T3/pl unknown
- 2015-08-03 UA UAA201909822A patent/UA123928C2/uk unknown
- 2015-08-03 US US15/501,079 patent/US9993484B2/en active Active
- 2015-08-03 MX MX2017001637A patent/MX376270B/es active IP Right Grant
- 2015-08-03 RS RS20180844A patent/RS57445B1/sr unknown
- 2015-08-03 PE PE2017000168A patent/PE20170666A1/es unknown
- 2015-08-03 LT LTEP18167649.5T patent/LT3395818T/lt unknown
- 2015-08-03 KR KR1020177005715A patent/KR102180006B1/ko active Active
- 2015-08-03 JP JP2017506353A patent/JP6266839B2/ja active Active
- 2015-08-03 EP EP18167649.5A patent/EP3395818B1/en active Active
- 2015-08-03 MA MA40523A patent/MA40523B1/fr unknown
- 2015-08-03 RS RS20211453A patent/RS62609B1/sr unknown
- 2015-08-03 UA UAA201702047A patent/UA121036C2/uk unknown
- 2015-08-03 ES ES15744596.6T patent/ES2679625T3/es active Active
- 2015-08-03 SI SI201531743T patent/SI3395818T1/sl unknown
- 2015-08-03 DK DK15744596.6T patent/DK3177619T3/en active
- 2015-08-03 TN TN2017000027A patent/TN2017000027A1/en unknown
- 2015-08-03 AU AU2015299173A patent/AU2015299173B2/en active Active
- 2015-08-03 CN CN201910654241.0A patent/CN110256427B/zh active Active
- 2015-08-03 MY MYPI2017700348A patent/MY192883A/en unknown
- 2015-08-03 KR KR1020207032608A patent/KR102317169B1/ko active Active
- 2015-08-03 PT PT157445966T patent/PT3177619T/pt unknown
- 2015-08-03 HR HRP20181143TT patent/HRP20181143T1/hr unknown
- 2015-08-03 CN CN201910654243.XA patent/CN110204544B/zh active Active
- 2015-08-04 UY UY0001036254A patent/UY36254A/es active IP Right Grant
-
2016
- 2016-05-19 US US15/159,548 patent/US9549932B2/en active Active
-
2017
- 2017-01-22 IL IL250220A patent/IL250220B/en active IP Right Grant
- 2017-02-01 SA SA517380830A patent/SA517380830B1/ar unknown
- 2017-02-03 DO DO2017000038A patent/DOP2017000038A/es unknown
- 2017-02-03 EC ECIEPI20177538A patent/ECSP17007538A/es unknown
- 2017-02-03 CO CONC2017/0001035A patent/CO2017001035A2/es unknown
- 2017-02-03 NI NI201700011A patent/NI201700011A/es unknown
- 2017-02-03 CL CL2017000287A patent/CL2017000287A1/es unknown
- 2017-12-19 JP JP2017242618A patent/JP6507216B2/ja active Active
-
2018
- 2018-05-08 US US15/974,536 patent/US10772893B2/en active Active
- 2018-07-24 CY CY181100768T patent/CY1120673T1/el unknown
-
2019
- 2019-06-13 AU AU2019204125A patent/AU2019204125B2/en active Active
- 2019-08-27 IL IL268969A patent/IL268969B/en active IP Right Grant
-
2020
- 2020-08-21 US US16/999,832 patent/US11529356B2/en active Active
-
2021
- 2021-02-15 ZA ZA2021/01003A patent/ZA202101003B/en unknown
- 2021-04-10 PH PH12021550792A patent/PH12021550792A1/en unknown
- 2021-12-09 CY CY20211101085T patent/CY1124855T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| BR112016018604A2 (pt) | Benzimidazol-2-aminas como inibidores de midh1 | |
| BR112017012327A8 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| BR112019008458A2 (pt) | 1,2,4-triazolonas 2,4,5-trisubstituídas. | |
| BR112016021648A2 (pt) | novos compostos | |
| BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
| BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| BR112015020990A2 (pt) | imidazopiridazinas substituídas | |
| BR112016011472A2 (pt) | tienopirimidinas como inibidores de mknk1 e mknk2 | |
| BR112016022749A2 (pt) | compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2 | |
| BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
| BR112017011980A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção bacteriana. | |
| BR112016021656A2 (pt) | inibidores das vias de sinalização de wnt | |
| MX390688B (es) | Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos. | |
| UY37032A (es) | Compuestos de heteroarilbenzimidazol | |
| MA39762A (fr) | Nouveaux composés |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2015, OBSERVADAS AS CONDICOES LEGAIS |